Frontlight ResearchEarly access
Taking people in United StatesNo phase
Early Feasibility Study of the Capstan Medical TMVR System
Key facts
- Who runs it
- Capstan Medical
- Where
- Cincinnati, Nashville, and San Francisco, United StatesSee the 3 sites
- Trial code
- Status
- Recruiting
- People taking part
- 15 people, planned
- Started
- Nov 2026
- Expected to end
- Mar 2032
- Type of study
- Interventional
- Treatments tested
- Capstan Compass Robotic System for Transcatheter Mitral Valve Replacement
- Record updated
- 9 November 2026
Who can take part
- Age
- 18 years and older
- Sex
- Women and men
- Healthy volunteers
- Cannot take part
The registry criteria, word for word
Show all 37 criteriaShow less
Who can take part
- Age ≥ 18 years at the time of consent
- Moderate-to-severe or severe mitral regurgitation
- NYHA II or greater symptoms
- The participant is considered to be at elevated, but not prohibitive, surgical risk for mitral valve replacement, as determined by the local multi-disciplinary heart team and/or a validated surgical risk assessment tool (e.g., STS PROM)
- The local multi-disciplinary heart team determines that surgical mitral valve replacement is not the preferred treatment option and that the participant is an appropriate candidate for treatment with the Capstan System
- The local multi-disciplinary heart team determines that the participant is unsuitable for mitral transcatheter edge-to-edge repair (mTEER) due to anatomical, technical, and/or clinical reasons
- The local multi-disciplinary heart team deems heart failure management is optimized based on participant characteristics and applicable guidelines
- Ability and willingness to provide written informed consent prior to any study related procedure(s)
Who cannot take part
- Prior mitral valve intervention that would interfere with the appropriate placement of the Capstan Valve
- Any cardiac or vascular procedure performed within 30 days prior to procedure
- Myocardial infarction within 30 days prior to enrollment
- Concurrent medical condition with a life expectancy of less than 12 months
- Participant is on the waiting list for a heart transplant or has had a prior heart transplant
- Currently enrolled in any other pre-approval investigational study (does not apply to long-term post-market studies unless these studies might clinically interfere with the current study endpoints (e.g., limit use of study-required medication, etc.))
- Untreated severe aortic or pulmonic valve disease (stenosis or regurgitation)
- Untreatable severe right ventricular dysfunction or severe tricuspid valve disease
- Cardiac resynchronization therapy (CRT) device implanted within 30 days of procedure
- Active endocarditis, other ongoing infection requiring antibiotic therapy
- Stroke or transient ischemic attack (TIA) within 30 days of procedure
- Active peptic ulcer or active gastrointestinal bleeding
- Known allergy or hypersensitivity to device materials (e.g. nitinol, PET), or a documented allergy to heparin, that cannot be adequately medicated; a history of HIT, or contraindication to required antithrombotic therapies
- Any condition making it unlikely the patient will be able to complete all protocol procedures (including compliance with guideline directed medical therapy) and follow-up visits
- Clinically significant untreated coronary artery disease requiring revascularization
- Chronic Obstructive Pulmonary Disease (COPD) on continuous O2 therapy
- Planned cardiac intervention in the next 12 months
- LVEF < 25%
- End-stage renal failure on dialysis or eGFR ≤ 25
- Pregnant (participants of childbearing age are required to have a negative pregnancy test)
- Anatomic features unsuitable for the Capstan System
- Inappropriate anatomy for femoral venous introduction and delivery of the Capstan System
- Severe mitral stenosis
- Evidence of intracardiac thrombus, vegetation, or mass
- PASP > 70mmHg or PVR > 5 Wood units after vasodilator challenge
- Contraindication to or inability to tolerate the protocol-required therapeutic anticoagulation regimen for the 6-months post-procedure period
- Participant is contraindicated for transesophageal echocardiography (TEE)
- Hemodynamic instability requiring inotropic or mechanical support within 30 days of the procedure
- Refusal of blood products
This trial is currently available in United States.
- The Christ HospitalCincinnati, United StatesContact: Susie FrakesTaking people
- Vanderbilt University Medical CenterNashville, United StatesContact: Kathryn AdamsNot yet recruiting
- Kaiser PermanenteSan Francisco, United StatesContact: Cristina Casias-PerezNot yet recruiting
About the trial
What the trial wants to find out
This early feasibility study is evaluating the safety and performance of the Capstan Compass Robotic System™ for transcatheter mitral valve replacement in patients with symptomatic, moderate-to-severe or severe mitral regurgitation who are unsuitable for surgical repair or transcatheter edge-to-edge repair.
The group in the trial
- TMVRTreatment being tested
Participants will undergo transcatheter mitral valve replacement
Treatment: Capstan Compass Robotic System for Transcatheter Mitral Valve Replacement
Questions to ask the study team
- How often do I need to come in, and for how long each time?
- Are travel costs paid?
- Can I keep my own doctor?
- What happens if I want to stop?
Contact the study team: see the registry record → Contacts and Locations
Print a page for my doctorData and sources
- Registry record
- Listed on ClinicalTrials.gov.How to verify a trial in the registry
- Record updated
- 9 November 2026